Q1 Earnings Forecast for Geron Issued By Leerink Partnrs

Key Points

• Leerink Partners forecasts Geron Corporation's Q1 2026 earnings per share (EPS) at ($0.03), while the full-year earnings estimate stands at ($0.25) per share.
• Geron reported Q2 earnings of ($0.02) EPS, exceeding analysts' expectations, with revenue growing by 5455.6% year-over-year to $49.04 million.
• Institutional ownership of Geron stock is significant, with 73.71% of shares held by institutional investors and hedge funds.

Geron Corporation (NASDAQ:GERN - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for shares of Geron in a report released on Tuesday, August 12th. Leerink Partnrs analyst F. Khurshid anticipates that the biopharmaceutical company will post earnings of ($0.03) per share for the quarter. The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron's Q2 2026 earnings at ($0.02) EPS and Q4 2026 earnings at $0.00 EPS.

Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.03) by $0.01. Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%. The company had revenue of $49.04 million during the quarter, compared to analysts' expectations of $47.30 million. During the same quarter in the previous year, the business earned ($0.10) EPS. Geron's revenue was up 5455.6% compared to the same quarter last year.

Several other equities research analysts have also recently weighed in on the company. Scotiabank cut Geron from a "sector outperform" rating to a "sector perform" rating and lowered their target price for the stock from $4.00 to $1.50 in a report on Thursday, May 8th. The Goldman Sachs Group began coverage on Geron in a report on Thursday, July 10th. They issued a "sell" rating and a $1.00 target price for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Geron presently has a consensus rating of "Moderate Buy" and an average price target of $4.19.

Geron Trading Up 0.3%

GERN traded up $0.01 during trading hours on Thursday, reaching $1.44. 1,031,460 shares of the company's stock traded hands, compared to its average volume of 12,722,477. The firm has a 50-day moving average price of $1.38 and a 200 day moving average price of $1.64. Geron has a 52-week low of $1.09 and a 52-week high of $4.83. The company has a quick ratio of 6.79, a current ratio of 7.87 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $915.56 million, a PE ratio of -10.98 and a beta of 0.73.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Geron by 2.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company's stock valued at $627,000 after purchasing an additional 8,123 shares during the period. Frisch Financial Group Inc. boosted its stake in shares of Geron by 84.3% in the first quarter. Frisch Financial Group Inc. now owns 19,025 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 8,700 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of Geron by 38.9% in the fourth quarter. Bank of Montreal Can now owns 33,147 shares of the biopharmaceutical company's stock worth $117,000 after acquiring an additional 9,277 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of Geron in the fourth quarter worth approximately $36,000. Finally, Savant Capital LLC boosted its stake in shares of Geron by 73.8% in the second quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company's stock worth $37,000 after acquiring an additional 11,074 shares during the last quarter. 73.71% of the stock is owned by institutional investors and hedge funds.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.